Clinical trial: An open-label, randomised trial of different re-start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B.

Asgeir JohannessenDag Henrik ReikvamSoo AlemanNega BerheNina WeisHailemichael DesalegnTore StenstadLars HeggelundEllen SamuelsenLars Normann KarlsenKarin LindahlFrank Olav PettersenJonas IversenElisabeth KleppaSigne BollerupAnni Assing WinckelmannPascal Brugger-SynnesHans Erling SimonsenJan SvendsenAnne-Marte Bakken KranMarte HolmbergInge Christoffer OlsenCorina Silvia RueeggOlav Dalgard

Published in: Alimentary pharmacology & therapeutics (2024)

We could not confirm our hypothesis that a higher threshold for restart of therapy after NA withdrawal improves the likelihood of HBsAg loss within 36 months in patients with HBeAg negative CHB. Further studies including only patients with HBsAg level <1000 IU/mL and/or larger sample size and longer follow-up duration are recommended.

Keyphrases

hepatitis b virus
clinical trial
open label
study protocol
phase ii
randomized controlled trial
double blind
stem cells
case control
phase iii